Sign In
Buy ATRC
$37.76
-2.39 (-5.95%)
At Close: Jul 31, 2026
AtriCure to Participate in Upcoming Investor Conferences
08:00am, Monday, 27'th Oct 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Announce Third Quarter 2025 Financial Results
08:00am, Wednesday, 08'th Oct 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
08:00am, Wednesday, 20'th Aug 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure (ATRC) Q2 Revenue Jumps 17%
03:19pm, Wednesday, 30'th Jul 2025
AtriCure (ATRC) Q2 Revenue Jumps 17%
AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript
07:14pm, Tuesday, 29'th Jul 2025
AtriCure, Inc. (NASDAQ:ATRC ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Angela L. Wirick - Chief Financial Officer Michael H.
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
06:31pm, Tuesday, 29'th Jul 2025
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
06:11pm, Tuesday, 29'th Jul 2025
AtriCure (ATRC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.17 per share a year ago.
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
04:01pm, Tuesday, 29'th Jul 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
08:00am, Monday, 28'th Jul 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
08:00am, Tuesday, 15'th Jul 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain
AtriCure to Announce Second Quarter 2025 Financial Results
08:00am, Tuesday, 08'th Jul 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
08:00am, Friday, 23'rd May 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
11:00am, Thursday, 15'th May 2025
The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript
09:34pm, Tuesday, 29'th Apr 2025
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Ex
AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
06:30pm, Tuesday, 29'th Apr 2025
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
